Refer-A-Friend Program
Sneeze, Wheeze and Itch Associates, LLC
Clinical Trial: COPD 2022-2026 (40+ years old)
A COPD Clinical Research Study is seeking participants aged 40 or above.
You or someone you know may be eligible for a study and receive compensation for time and travel.
Sign up here or contact us and our research coordinator will be in touch for screening.
COPD Therapy Study
A research study to evaluate asthma treatment in teens is open for enrollment. Study-related procedures and study medication are covered at no cost to you. Participants who qualify will be compensated for time and reasonable expenses for their visits. It is a great opportunity to receive close care by doctors you trust.
View this study on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05166889
What is COPD? Read our info page: https://asthma2.com/news/chronic-obstructive-lung-disease-copd-resources/
Eligibility Requirements:
– Be older than 39 years old by the time the study begins
– Be diagnosed with COPD for at least 1 year at the time the study begins and had some history of smoking.
Study Details:
– The study will evaluate a potential COPD treatment.
If you or someone you know may be interested in learning more about the study and eligibility, please sign up in our interest form. Our clinical trial staff will contact you for screening.
Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or email us at research@asthma2.com
______________________________
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: November 2024 (study valid until 2026)
Clinical Trial: Asthma Study 2024-2027 (12-17 years old)
Are you or your child diagnosed with Asthma for at least 1 year and between the ages of 12-17?
You may be eligible for a study and receive compensation for time and travel
Sign up here or contact us and our research coordinator will be in touch for screening.
Asthma Therapy Study
A research study to evaluate asthma treatment in teens is open for enrollment. Study-related procedures and study medication are covered at no cost to you. Participants who qualify will be compensated for time and reasonable expenses for their visits. It is a great opportunity to receive close care by doctors you trust.
View this study on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT055740102
What is Asthma? Read our info page: https://asthma2.com/news/asthma-resources
Eligibility Requirements:
– Be 12-17 years of age
– Be diagnosed with Asthma for at least 1 year at the time the study begins
Study Details:
– The study will compare a triple or dual asthma treatment over 24-weeks period.
If you meet these requirements, please sign up in our interest form. Our clinical trial staff will contact you for screening.
Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or Kady 309-452-0995 Ext 7522. Or
email us at research@asthma2.com
______________________________
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: August 2024 (study valid until 2027)
Clinical Trial: Celiac Disease Study 2024-2025
Do you have Celiac Disease?
Are you between the ages of 18-70?
Have you been on a gluten free diet for at least 12 months?
If yes, you may be qualified to enroll in a paid study at our center in Normal, IL,
Sign up here or contact us and our research coordinator will be in touch for screening.
Celiac Disease Study
A research study to evaluate the safety and efficacy of an investigational medication for Celiac Disease is open for enrollment. Study-related procedures and study medication are covered at no cost to you. Participants who qualify will be compensated for time and reasonable expenses for their visits. It is a great opportunity to receive close care by doctors you trust.
View this study on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05574010
What is Celiac Disease? Read our info page: https://asthma2.com/celiac-disease
Image by freepik
Eligibility Requirements:
– Be 18 – 70 years of age
– Be diagnosed with Celiac Disease (diagnosed through blood work and intestinal biopsy)
– Have been on a gluten free diet for at least 12 months
Study Details:
– The study drug will be compared with a placebo to find out if the study drug is better than the placebo for treatment of celiac disease. The placebo looks like the study drug but does not contain the active ingredient.
– If enrolled, you will be randomly selected to receive 3 treatments of either the study medication or the placebo over a one-week timeframe. You will be monitored for 4 hours at the clinic after every infusion.
– Total study duration, including screening, is approximately 13 months with 10 office visits.
– Your medical records will be needed to confirm your celiac disease diagnosis. Please make sure you have access to these reports so that the study team can review them.
If you meet these requirements, please sign up in our interest form. Our clinical trial staff will contact you for screening.
______________________________
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: August 2024 (study valid until December 2025)
______________________________
Clinical Trial: Call for Moderate-Severe Eczema/Atopic Dermatitis Patients
Are you 18 years old and above?
Have you had moderate to Severe Eczema/Atopic Dermatitis for at least three years?
We accept participants of all sexes.
You may be eligible for a study and receive compensation for time and travel.
See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.
BRIEF SUMMARY
This study aims to see if ADX-914 are safe and effective to treat people with eczema. We’ll compare the results of the medication against a placebo treatment.
CONDITIONS
Atopic Dermatitis
INTERVENTION / TREATMENT
Medication, Placebo
ENROLLMENT NATIONWIDE (ESTIMATED)
110
STUDY TYPE
Interventional
PHASE
Phase 2
AGES ELIGIBLE FOR STUDY
12 Years and above (Adult, Older Adult)
SEXES ELIGIBLE FOR STUDY
All
ACCEPTS HEALTHY VOLUNTEERS
No
Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05509023
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: August 2023
________________________________
Study Participation Details
About Trials and SWIA CRC
All our clinical research opportunities are FDA regulated and are sponsored by pharmaceutical companies or government agencies to develop new treatments or to study additional diseases for treatments currently approved for prescription. Each trial is conducted at many academic and private research centers that have been carefully chosen for their experience and reputation. SWIA Clinical Research Center, is a separate company affiliated with Midwest Allergy Sinus & Respiratory has operated over 1000 trials over the past 30 years and has been involved in developing many of the allergy and respiratory medicines you may be familiar with, including Zyrtec, Allegra, Singulair, Advair, Symbicort, Breztri, Trelegy, Nasonex, Xhance, Grastek, Ragwitek, Xolair, Dupixent, Palforzia, Stelara, Opzelura, Cibinqo, and Rinvoq, to name a few. Our highly trained clinical research staff follow strict protocols, which are in place to ensure safety, uniformity, and integrity. We have conducted studies with Volunteers from all walks of life, from infancy through advanced ages.
Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or Kady 309-452-0995 Ext 7522. You can also email us at research@asthma2.com, or fill out this contact this form.
Clinical Study: Peanut Allergy (ALK)
Adults and children ages 4 to 65 may be eligible to participate in a clinical study for peanut allergies.
Study participants will receive study-related care at no cost.
See if you are eligible for this paid study by filling out this form.
You will be contacted by our staff as soon as possible.
FARE in collaboration with ALK Pharmaceuticals, are working on a study to assess the safety and tolerability of a once-daily sublingual immunotherapy (SLIT) tablet for peanut allergy. The peanut SLIT-tablet is being developed for peanut-allergic patients to reduce allergic reactions that may occur following accidental exposure to peanut. By desensitizing patients to peanut protein, tolerance is increased and consequently protects against allergic reactions upon accidental peanut exposure.
Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05440643
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials in Normal, IL or Springfield, IL here.
Page updated: January 2024
Clinical Study: Eosinophilic Esophagitis / EoE (CROSSING 2023-2027)
Are you an adult between 12-80 or with a child 12 years old or above?
Do you have physician-documented Eosinophilic Esophagitis (EoE)?
Read: What is EoE? and Top 11 FAQs about EoE
Do you have difficulty swallowing food?
We accept participants of all sexes.
You may be eligible for a study with compensation for time and travel to our site in Normal, IL.
See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.
BRIEF SUMMARY
Researchers are testing if a new medicine named tezepelumab, given as a shot with a special syringe, works better and is safe for people with eosinophilic esophagitis, compared to a placebo.
CONDITIONS
EoE (Eosinophilic Esophagitis)
ENROLLMENT GLOBALLY (ESTIMATED)
360
STUDY TYPE
Interventional
PHASE
Phase 3
AGES ELIGIBLE FOR STUDY
12-80 Years (Child, Adult, Older Adult)
SEXES ELIGIBLE FOR STUDY
All
ACCEPTS HEALTHY VOLUNTEERS
No
Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05583227
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: December 2023
Clinical Study: Severe Asthma NIMBLE (Continued Care) 2023 2024
Are you an adult or with a child 12 years old or above who has severe asthma?
Do you have documented physician diagnosis of asthma for 2 years or more?
We accept participants of all sexes.
You may be eligible for a study with compensation for time and travel up to $2000.
See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.
Image Credit: Polina Tankilevitch (Pexel)
BRIEF SUMMARY
Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment. The study will assess switching types of biologic medication.
CONDITIONS
Asthma
INTERVENTION / TREATMENT
Biological
ENROLLMENT GLOBALLY (ESTIMATED)
1700
STUDY TYPE
Interventional
PHASE
Phase 3
AGES ELIGIBLE FOR STUDY
12 Years and older (Child, Adult, Older Adult)
SEXES ELIGIBLE FOR STUDY
All
ACCEPTS HEALTHY VOLUNTEERS
No
Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT04718389
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: December 2023
Clinical Trial: Call for Moderate-Severe Eczema Patients (SIGNAL-AD)
Are you 18 years old and above?
Have you had moderate to Severe Eczema/Atopic Dermatitis for at least three years?
We accept participants of all sexes.
You may be eligible for a study and receive compensation for time and travel.
See if you are eligible by filling out this form. You will be contacted by our staff as soon as possible.
BRIEF SUMMARY
This study aims to see if ADX-914 are safe and effective to treat people with eczema. We’ll compare the results of the medication against a placebo treatment.
CONDITIONS
Atopic Dermatitis
INTERVENTION / TREATMENT
Medication, Placebo
ENROLLMENT NATIONWIDE (ESTIMATED)
110
STUDY TYPE
Interventional
PHASE
Phase 2
AGES ELIGIBLE FOR STUDY
12 Years and above (Adult, Older Adult)
SEXES ELIGIBLE FOR STUDY
All
ACCEPTS HEALTHY VOLUNTEERS
No
Read on Clinicaltrial.gov: https://clinicaltrials.gov/study/NCT05509023
Why participate in clinical research? All of the medicines you currently take for your health were first studied in clinical trials before the FDA approved them. It is a great way to help your community, while getting close care and monitoring by doctors you know.
See other active clinical trials here.
Page updated: August 2023
________________________________
Study Participation Details
About Trials and SWIA CRC
All our clinical research opportunities are FDA regulated and are sponsored by pharmaceutical companies or government agencies to develop new treatments or to study additional diseases for treatments currently approved for prescription. Each trial is conducted at many academic and private research centers that have been carefully chosen for their experience and reputation. SWIA Clinical Research Center, is a separate company affiliated with Midwest Allergy Sinus & Respiratory has operated over 1000 trials over the past 30 years and has been involved in developing many of the allergy and respiratory medicines you may be familiar with, including Zyrtec, Allegra, Singulair, Advair, Symbicort, Breztri, Trelegy, Nasonex, Xhance, Grastek, Ragwitek, Xolair, Dupixent, Palforzia, Stelara, Opzelura, Cibinqo, and Rinvoq, to name a few. Our highly trained clinical research staff follow strict protocols, which are in place to ensure safety, uniformity, and integrity. We have conducted studies with Volunteers from all walks of life, from infancy through advanced ages.
Contact us for more information, SWIA Clinical Research Dept.: Stephanie 309-451-7509 or Kady 309-452-0995 Ext 7522. You can also email us at research@asthma2.com, or fill out this contact this form.
Great News: Positive Top-Line Result for Safety and Efficacy of a Non-Steroidal Topical Treatment for Atopic Dermatitis in Children (MASA SWIA)
On July 11, 2023, MASA’s research team at Sneeze Wheeze and Itch Associates received great news regarding the positive top-line research results on the safety and efficacy of a non-steroidal topical treatment for Atopic Dermatitis (AD) in children. The SWIA research team, led by Dr. Siri as Principal Investigator, contributed to the pivotal Phase 3 study for ruxolitinib cream, along with 98 other research centers worldwide!
Incyte, a pharmaceutical company, has released positive results from a study evaluating a cream called ruxolitinib (Opzelura®) for the treatment of atopic dermatitis (AD) in children. AD is a chronic skin condition that affects about 13% of children in the U.S. The study showed that more patients treated with ruxolitinib cream achieved successful treatment compared to those treated with a non-medicated cream. The cream was well-tolerated, and no new safety concerns were observed. Incyte plans to discuss these positive results with regulatory agencies to determine the next steps.
Atopic dermatitis (AD), the most common type of eczema, affects millions of people in the U.S., particularly children. It is characterized by inflamed and itchy skin, which can cause discomfort and infections. The recently completed study, called TRuE-AD3, enrolled over 300 children aged 2 to 12 years who had been diagnosed with AD for at least three months. The primary goal of the study was to assess the proportion of patients achieving successful treatment based on specific criteria. The study results will be presented at a scientific meeting.
Opzelura cream is a formulation of ruxolitinib, a medication that targets specific pathways in the body associated with inflammation. It has already been approved for the treatment of vitiligo and atopic dermatitis in the U.S. Opzelura offers a potential non-steroidal topical therapy for children with AD, which could provide relief from symptoms and improve their quality of life. Incyte holds the worldwide rights for the development and commercialization of ruxolitinib cream.
Read about the clinical trial here: https://classic.clinicaltrials.gov/ct2/show/NCT04921969
Read more about the announcement here: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-topline-results-phase-3-trial
Follow Sneeze, Wheeze and Itch Associates on Facebook: https://www.facebook.com/SWIA.Clinical.Research
Refer-A-Friend Program
REFER A QUALIFYING FRIEND,
AND YOU COULD RECEIVE UP TO $25!
How It Works
To refer a friend or family member for a clinical trial at SWIA and earn up to $25, simply:
1. Print and fill out a Refer-A-Friend coupon (click here to download).
2. Your friend or family member must contact SWIA about the research study and present this coupon at their first study visit.
3. If your friend or family member qualifies to screen for the study and enrolls (randomizes and receives study medication, study treatment or placebo), the referrer (YOU) will earn $25!
Please Remember
-You can refer as many people as you want and there is no limit to how much money you can make!
-To be eligible, the friend or family member that you refer must be new to our database, and YOU must be in our database as well. To be added to our database, call 309-452-0995 and ask to speak to a research coordinator.
-The decision to participate in a study is up to your friend or family member.
-Refer-A-Friend payments are made AFTER your friend or family member has completed the randomization visit.
-For questions about the Refer-A-Friend program or to inquire about the status of a referral, please call 309-452-0995.
For more information regarding current studies, please call 309-452-0995 and ask to speak to a coordinator.